Sawhney Roger 4

What Happened

• Roger Sawhney, a director of Arbutus Biopharma Corp (NASDAQ: ABUS), received a grant/award on 2026-06-08 covering 78,800 derivative shares (reported as acquisition code "A"). The Form 4 reports a $0.00 cash price for the grant (derivative award), and a footnote says the closing market price on the grant date is referenced but not shown in the filing. The filing also states the option is fully vested and exercisable as of the grant date.

Key Details

• Transaction date: 2026-06-08; Form 4 filed: 2026-06-10 (timely filing).
• Transaction type: Award/Grant of derivative securities (code A); reported price $0.00 because this is a grant, not a cash purchase or sale.
• Quantity: 78,800 derivative shares (options/rights).
• Vesting/exercisability: Footnote indicates the option is fully vested and exercisable as of the grant date.
• Market value/strike: The filing references the closing price on Nasdaq for valuation (footnote) but does not specify a strike price or dollar value in the provided excerpt.
• Shares owned after transaction: Not specified in the provided details.

Context

• This was an equity award (derivative security) rather than an open-market buy or sale. That means Sawhney received the right to acquire shares (an option-like award) rather than immediately purchasing or selling common stock.
• Awards to directors are common as compensation and do not by themselves signal buying or selling sentiment; they represent potential future equity if exercised or vested.